EUVIMEDEUVIMED entdecken
Crossref

Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer

Yoshitaka Saito, Yoh Takekuma, Masato Takahashi, Tomohiro Oshino, Mitsuru Sugawara

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08733-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Yoshitaka Saito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Te…. Hauptthemen laut MEDLINE: Breast Neoplasms, Docetaxel, Cyclophosphamide, Stomatitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy is effective for perioperative breast cancer treatment. However, these treatments frequently induce oral mucositis (OM), with an incidence ranging from 20 to 50%. The association of OM development between different chemotherapeutic treatments remains unclear. Consequently, this study aimed to compare OM development during docetaxel-containing chemotherapy between patients with and without OM experience during previous anthracycline-cyclophosphamide treatments to assess the association between OM development and treatment regimens. METHODS: Seventy-two patients with breast cancer receiving anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy as a perioperative treatment were categorized into the control (no prior OM experience with anthracycline-cyclophosphamide) and OM-experience (OM development during previous treatment) groups and retrospectively evaluated. The primary endpoint was the incidence of all-grade OM in the first docetaxel-containing chemotherapy cycle. Additionally, the incidences of OM and dysgeusia during all treatment cycles and factors associated with the incidence of OM were evaluated. RESULTS: The incidence of all-grade OM in the first cycle was significantly higher in the OM-experience group (54.2%) than in the control group (10.4%; P < 0.0001). Furthermore, its incidence in all treatment cycles was higher in the OM-experience group (66.7%) than in the control group (12.5%, P < 0.0001). However, the incidence of dysgeusia did not differ between the groups. Multivariate logistic regression analysis revealed OM experience during previous anthracycline-cyclophosphamide treatment and concomitant pertuzumab use as independent risk factors for OM development in subsequent docetaxel-containing chemotherapy. CONCLUSION: Our study suggests that patients experiencing OM with anthracycline-cyclophosphamide during perioperative breast cancer treatment exhibit symptoms following subsequent docetaxel-containing chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDocetaxelCyclophosphamideStomatitisAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesHumansFemaleMiddle AgedRetrospective StudiesAdultAgedIncidenceTaxoidsRisk Factors

Stichwörter der Autor:innen

AnthracyclineCyclophosphamideDocetaxelDysgeusiaOral mucositis

Substanzen

DocetaxelCyclophosphamideAnthracyclinesTaxoids

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Teine-Ku, Sapporo, 006-8585, Japan. saito-yo@hus.ac.jp.
  • Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan. saito-yo@hus.ac.jp.
  • Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
  • Department of Breast Surgery, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
  • Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-Jo, Nishi 6-Chome, Kita-Ku, Sapporo, 060-0812, Japan.

Zitieren

APA

Saito, Y., Takekuma, Y., Takahashi, M., Oshino, T., & Sugawara, M. (2024). Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08733-7

Vancouver

Saito Y, Takekuma Y, Takahashi M, Oshino T, Sugawara M. Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08733-7

BibTeX
@article{Saito2024,
  author = {Saito, Yoshitaka and Takekuma, Yoh and Takahashi, Masato and Oshino, Tomohiro and Sugawara, Mitsuru},
  title = {Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08733-7}
}
Kostenlos starten →